Arcadia Biosciences Inc reports results for the quarter ended in December - Earnings Summary

Arcadia Biosciences

30/03/2023 22:39

* Arcadia Biosciences Inc  RKDA.OQ  reported a quarterly
adjusted
loss of $6.29​​ per share for the quarter ended in December. The
mean expectation of two analysts for the quarter was for a loss
of $6.80 per share.
    * Revenue fell 53.9% to $1.00 million from a year ago;
analysts
expected $2.00 million. 
    * Arcadia Biosciences Inc's reported EPS for the quarter was
a
loss of $7.08​.
    * The mean earnings estimate of analysts had risen by
about 2.9%
in the last three months.​ 
    * In the last 30 days, there have been no earnings estimate
revisions by analysts covering the company. 
    * Arcadia Biosciences Inc shares had fallen by 27.4% this
quarter.
    * The company reported a quarterly loss of $4.24 million.
    * Wall Street's median 12-month price target for Arcadia
Biosciences Inc is $100.00 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 1 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell." 

This summary was machine generated from LSEG Refinitiv data
March 30 at 09:39 p.m. UTC. ​All figures in US dollars unless
otherwise stated. QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Dec. 31 2022      -6.80          -6.29          Beat
 Sep. 30 2022      -8.40          -4.80          Beat
 Jun. 30 2022      -12.00         -8.00          Beat
 Mar. 31 2022      -13.60         -8.00          Beat